

PTO/SB/08A (08-03)

Substitute for Form PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete If Known

Application Number	10/008,244
Filing Date	November 7, 2001
First Named Inventor	Huang, Alan
Art Unit	1005 1653
Examiner Name	To Be Assigned
Attorney Docket Number	018781-005510US

RECEIVED
SEP 23 2003
TECH CENTER 1800/2900**U.S. PATENT DOCUMENTS+**

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	class/subclass Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1.	5,591,825		01-07-1997	McKnight et al.	530-350
	2.	5,639,858		08-1997	Hoey et al.	530-350
	3.	5,710,266		01-1998	McKnight et al.	536-23.5
	4.	5,718,822 A		02-10-1998	Darnell, Jr. et al.	424-185.1
	5.	5,731,155 A		03-24-1998	Schreiber et al.	435-7.1
	6.	5,591,825		01-1997	McKnight et al.	530-350
	7.	6,426,331 B1		07-30-2003	McKinney et al.	514-009

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Country Code ³	Number ⁴	Kind Code ⁴ (if known)				
X	8.	JP	10176984		08-30-1998	Sumitomo Seiyaku KK		
X	9.	JP	10176985		08-30-1998	Sumitomo Seiyaku KK		
X	10.	JP	11106340		04-20-1999	Sumitomo Seiyaku KK		
X	11.	JP	11116481		04-27-1999	Sumitomo Seiyaku KK		
X	12.	JP	2000-229850	A1	08-22-2000	Sumitomo Chem Co Ltd		
DL	13.	WO	87/05182	A1	02-13-1987	BASF Aktiengesellschaft	---	
DL	14.	WO	98/31704	A1	07-23-1998	Novartis Pharm.	---	
DL	15.	WO	99/24442	A1	05-20-1999	Ariad Pharm. Inc.	---	
DL	16.	WO	99/50283	A1	10-07-1999	Tularik Inc.	---	
DL	17.	WO	00/027802	A1	05-18-2000	Ariad Pharm. Inc.	---	
DL	18.	WO	01/83517	A1	11-08-2001	Tularik Inc.	---	

David L. H.

4/2/04

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60033536 v1



PTO/SB/08B (08-01)

Substitute for form 1449B PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/008,244
Filing Date	November 7, 2001
First Named Inventor	Huang, Alan
Art Unit	1653
Examiner Name	To Be Assigned
Attorney Docket Number	018781-005510US

RECEIVED
SEP 22 2003
TECH CENTER 1600-2900**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DL	19.	ANONYMOUS, "STAT antibodies" Research Diagnostics, pp. 1-9, March 26, 1998	
	20.	ANONYMOUS, "Stat sampler kit" The 1998 Online Antibody Catalog, Transduction Laboratories, 5 pages, March 29, 1998.	
	21.	ANONYMOUS, "The jak-STAT mechanism of signal transduction" The Cytokine Bulletin pp. 1-6 (1995) at <http://www.mdsystems.com/asp/b> (visited on January 8, 2003)	
	22.	BLOMMERS et al., "Transferred cross-correlated relaxation complements transferred NOE: Structure of an IL-4R- derived peptide bound to STAT-6" J. Am. Chem. Soc. 121(9):1949-1953 (1999)	
	23.	CARPENTER, "Receptor tyrosine kinase substrates: src homology domains and signal transduction" FASEB J. 6:3283-3289 (1992)	
DL	24.	DARNELL et al., "Jak-Stat pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins" Science 264:1415 (1994)	
	25.	HOU et al., "An interleukin-4-induced transcription factor: IL-4 stat" Science 265:1701-1708 (1994)	
	26.	IHLE et al., "Signaling by the cytokine receptor superfamily: JAKs and STATs" Trends Biochem Sci. 19:222-227 (1994)	
	27.	IHLE et al., "Jaks and Stats in signaling by the cytokine receptor superfamily" Trends Genetics 11:69-74 (1995)	
	28.	KAPLAN et al., "Impaired IL-12 responses and enhanced development of Th2 cells in stat4-deficient mice" Nature 382:174-177 (1996)	
	29.	KAPLAN, M. et al., "Stat6 is required for mediating responses to IL-4 and for the development of TH2 cells" Immunity 4:313-319 (1996)	
	30.	MARTIN, et al., "Sulfonic acid enkephalin: Binding specificity to rat brain opiate receptors" Neuropeptides 6:293-302 (1985)	
	31.	MYERS et al., "The IRS-1 signaling system" Trends in Biochem. Sci. 19:289-293 (1994)	
	32.	OSHIMA et al., "A novel interleukin-13 antagonist that blocks the biological activity of human interleukin-13 in immune and nonimmune cells" FASEB Journal 15(6):122-144 (2001)	
	33.	PAWSON, T. "Protein modules and signaling networks" Nature 373:573-580 (1995)	
DL	34.	QUELLE et al., "Cloning of murine Stat6 and Human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis" Mol. Cell. Biol. 15:338-3343 (1995)	
	35.	RYAN, J. et al., "Growth and gene expression are predominantly controlled by distinct regions of the human IL-4 receptor" Immunity 4:123-132 (1996)	

Examiner
Signature

David L. Latta

Date
Considered

4/2/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (08-03)

Substitute for form 1495B/PTO


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

Complete If Known

Application Number	10/008,244
Filing Date	November 7, 2001
First Named Inventor	Huang, Alan
Art Unit	1645
Examiner Name	To Be Assigned
Attorney Docket Number	018781-005510US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DL	36.	SCHINDLER, C. et al., "Transcriptional responses to polypeptide ligands: The JAK-STAT pathway" Annu. Rev. Biochem. 64:621-51 (1995)	
	37.	SCHLESSINGER, J. "SH2/SH3 signaling proteins" Curr. Opin. In Gen. and Dev. 4:25-30 (1994)	
	38.	SHUAI et al., "Polypeptide signaling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins" Nature 366:580-583 (1993)	
	39.	THIERFELDER et al., "Requirement for stat4 in interleukin-12 mediated responses of natural killer and T cells" Nature 382:171-174 (1996)	
	40.	WANG, H. et al., "IL-4 function can be transferred to the IL-2 receptor by tyrosine containing sequences found in the IL-4 receptor alpha chain" Immunity 4:113-121 (1996)	
	41.	YAMAMOTO et al., "cDNA cloning, expression and chromosome mapping of the human STAT4 gene: both STAT4 and STAT1 genes are mapped to 2q32.2-q32.3" Cytogenet Cell Genet. 77:207-210 (1997)	
DL	42.	YAO et al., "Direct interaction of STAT4 with the IL-12 receptor" Archives of Biochemistry and Biophysics 388(1):147-155 (1999)	
	43.	ZHONG et al., "Stat3 and Stat4: Members of the family of signal transducers and activators of transcription" Proc. Natl. Acad. Sci. USA 91:4806-4810 (1994)	

4/2/04

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.